New drug cocktail aims to wipe out bladder tumors before surgery

NCT ID NCT06133517

Ongoing Disease control Sponsor: Fundación para el Progreso de la Oncología en Cantabria Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of three drugs—sacituzumab govitecan, zimberelimab, and domvanalimab—given before and after surgery for muscle-invasive bladder cancer. The study includes 70 patients who cannot take standard cisplatin chemotherapy. The main goal is to see if the treatment can completely eliminate the tumor by the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab govitecan (Trodelvy), zimberelimab, and domvanalimab
What this could lead to: If this works, it could offer a new treatment option for people with muscle-invasive bladder cancer who cannot have standard chemotherapy, potentially eliminating the tumor before surgery.
What could go wrong: This is a small, early-phase trial with only 70 participants and no comparison group. The combination may cause significant side effects, and it is not yet known if it improves long-term survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma infiltrating bladder urothelial carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UROTHELIAL BLADDER CARCINOMA

Contacts and locations

Locations

Hospital Clinico Universitario de Valladolid

Valladolid, Valladolid, Spain
Hospital Clínico San Carlos

Madrid, Madrid, Spain
Hospital Duran i Reynals (ICO L´Hospitalet)

L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marqués de Valdecilla

Santander, Cantabria, Spain
Hospital Universitario de Navarra

Pamplona, Navarre, Spain
Hospital Virgen de la Salud

Toledo, Toledo, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.